NASDAQ:KROS

Keros Therapeutics (KROS) Competitors

$30.85

0.00 (0.00%)

(As of 10/4/2023 ET)

Compare

Today's Range: $30.23
▼
$31.06
50-Day Range: $30.82
▼
$42.68
52-Week Range: $30.23
▼
$59.96

Volume: 102,147 shs
Average Volume: 209,212 shs
Market Capitalization: $915.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $94.33

KROS vs. SLRN, ETNB, MIRM, TARS, CALT, OCS, ITOS, IDYA, ORIC, and MGTX

Should you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Acelyrin (SLRN), 89bio (ETNB), Mirum Pharmaceuticals (MIRM), Tarsus Pharmaceuticals (TARS), Calliditas Therapeutics AB (publ) (CALT), Oculis (OCS), iTeos Therapeutics (ITOS), IDEAYA Biosciences (IDYA), ORIC Pharmaceuticals (ORIC), and MeiraGTx (MGTX). These companies are all part of the "medical" sector.

Keros Therapeutics vs.

Keros Therapeutics (NASDAQ:KROS) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.

: Keros Therapeutics presently has a consensus price target of $94.33, indicating a potential upside of 205.78%. Acelyrin has a consensus price target of $37.00, indicating a potential upside of 290.71%. Given Acelyrin's higher probable upside, analysts plainly believe Acelyrin is more favorable than Keros Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Keros Therapeutics
0 Sell rating(s)
0 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
3.00
Acelyrin
0 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.80
: Acelyrin has lower revenue, but higher earnings than Keros Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Keros Therapeutics $20.10M 45.52 -$104.68M -$4.54 -6.80
Acelyrin N/A N/A -$64.77M N/A N/A
: Keros Therapeutics received 26 more outperform votes than Acelyrin when rated by MarketBeat users. However, 62.50% of users gave Acelyrin an outperform vote while only 60.78% of users gave Keros Therapeutics an outperform vote.
Company Underperform Outperform
Keros Therapeutics Outperform Votes
31
60.78%
Underperform Votes
20
39.22%
Acelyrin Outperform Votes
5
62.50%
Underperform Votes
3
37.50%
: Acelyrin's return on equity of 0.00% beat Keros Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Keros Therapeutics N/A -42.19% -38.93%
Acelyrin N/A N/A N/A
: In the previous week, Keros Therapeutics and Keros Therapeutics both had 2 articles in the media. Keros Therapeutics' average media sentiment score of 1.81 beat Acelyrin's score of 0.76 indicating that Keros Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Keros Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Acelyrin
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 75.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 94.7% of Acelyrin shares are held by institutional investors. 28.0% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Acelyrin	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$20.10M	45.52	-$104.68M	-$4.54	-6.80
Acelyrin	N/A	N/A	-$64.77M	N/A	N/A

Company	Underperform	Outperform
Keros Therapeutics	Outperform Votes 31 60.78%	Underperform Votes 20 39.22%
Acelyrin	Outperform Votes 5 62.50%	Underperform Votes 3 37.50%

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	N/A	-42.19%	-38.93%
Acelyrin	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Acelyrin	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Keros Therapeutics and Acelyrin tied by winning 6 of the 12 factors compared between the two stocks.

Get Keros Therapeutics News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KROS vs. The Competition

Export to Excel

Metric	Keros Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$915.01M	$5.37B	$4.28B	$6.30B
Dividend Yield	N/A	2.63%	2.41%	7.91%
P/E Ratio	-6.80	4.61	119.32	11.96
Price / Sales	45.52	141.16	2,883.57	52.39
Price / Cash	N/A	22.56	90.79	105.58
Price / Book	3.06	3.96	3.78	4.55
Net Income	-$104.68M	$155.63M	$121.35M	$181.77M
7 Day Performance	-3.71%	-3.60%	-2.64%	-2.06%
1 Month Performance	-14.87%	-12.47%	-8.66%	-9.16%
1 Year Performance	-24.01%	0.97%	4.37%	-0.79%

Keros Therapeutics Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLRN Acelyrin	2.0397 of 5 stars	$9.40 -3.8%	$37.00 +293.6%	N/A	$914.06M	N/A	0.00	79	Positive News
ETNB 89bio	1.96 of 5 stars	$14.40 -0.1%	$37.44 +160.0%	+160.9%	$1.09B	N/A	-6.82	45	Short Interest ↓
MIRM Mirum Pharmaceuticals	2.3872 of 5 stars	$29.77 +1.6%	$51.14 +71.8%	+37.7%	$1.14B	$77.06M	-6.27	213	Analyst Report Positive News Gap Up
TARS Tarsus Pharmaceuticals	2.1846 of 5 stars	$17.60 +0.9%	$46.40 +163.6%	+3.5%	$574.11M	$25.82M	-5.21	87	Positive News High Trading Volume
CALT Calliditas Therapeutics AB (publ)	2.1096 of 5 stars	$17.14 +0.6%	$49.00 +185.9%	+14.1%	$510.60M	$79.63M	-16.48	169	Positive News
OCS Oculis	1.6389 of 5 stars	$11.34 -3.5%	$33.40 +194.5%	N/A	$412.66M	$960,000.00	0.00	28	Analyst Report Gap Down
ITOS iTeos Therapeutics	1.9306 of 5 stars	$10.54 +1.2%	$36.33 +244.7%	-44.7%	$377.12M	$267.63M	-13.17	125	Analyst Revision
IDYA IDEAYA Biosciences	2.3279 of 5 stars	$25.52 -1.2%	$32.08 +25.7%	+72.1%	$1.47B	$50.93M	-17.60	116	Gap Down
ORIC ORIC Pharmaceuticals	2.0744 of 5 stars	$5.59 -5.1%	$15.00 +168.3%	+77.5%	$304.82M	N/A	-2.56	89	Positive News
MGTX MeiraGTx	2.5013 of 5 stars	$4.56 -1.9%	$25.67 +462.9%	-44.5%	$271.46M	$15.92M	-1.78	406	Positive News

Related Companies and Tools

Related Companies:

Top 10 Stock Comparisons

This page (NASDAQ:KROS) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Keros Therapeutics (KROS) Competitors

KROS vs. SLRN, ETNB, MIRM, TARS, CALT, OCS, ITOS, IDYA, ORIC, and MGTX

Keros Therapeutics vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info